Role of toll-like receptor 4 on the immune escape of human oral squamous cell carcinoma and resistance of cisplatin-induced apoptosis

[1]  N. Fausto,et al.  Toll‐like receptor 4 and myeloid differentiation factor 88 provide mechanistic insights into the cause and effects of interleukin‐6 activation in mouse liver regeneration , 2011, Hepatology.

[2]  J. Spicer,et al.  LPS-induced TLR4 signaling in human colorectal cancer cells increases beta1 integrin-mediated cell adhesion and liver metastasis. , 2011, Cancer research.

[3]  T. Whiteside,et al.  TLR4 signaling induced by lipopolysacharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer , 2009, Oncogene.

[4]  T. Whiteside,et al.  Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. , 2009, Cancer research.

[5]  Haiyang Xie,et al.  Regulation of TLR4-induced IL-6 response in bladder cancer cells by opposing actions of MAPK and PI3K signaling , 2009, Journal of Cancer Research and Clinical Oncology.

[6]  L. O’Neill.  When signaling pathways collide: positive and negative regulation of toll-like receptor signal transduction. , 2008, Immunity.

[7]  Lei Zhang,et al.  Characteristics of a cancerous cell line, HIOEC-B(a)P-96, induced by benzo(a)pyrene from human immortalized oral epithelial cell line. , 2008, Archives of oral biology.

[8]  Shizuo Akira,et al.  Signaling to NF-?B by Toll-like receptors , 2007 .

[9]  S. Rosenberg,et al.  Toll-like Receptors in Tumor Immunotherapy , 2007, Clinical Cancer Research.

[10]  Nan Li,et al.  TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. , 2007, Molecular immunology.

[11]  L. Hakansson,et al.  Preoperative interleukin‐6 production by mononuclear blood cells predicts survival after radical surgery for colorectal carcinoma , 2007, Cancer.

[12]  R. Chen,et al.  Inflammation, Cancer and Chemoresistance: Taking Advantage of the Toll‐Like Receptor Signaling Pathway , 2007, American journal of reproductive immunology.

[13]  D. Landsittel,et al.  Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. , 2006, Gynecologic oncology.

[14]  Masafumi Nakamura,et al.  Nuclear factor-kappaB contributes to hedgehog signaling pathway activation through sonic hedgehog induction in pancreatic cancer. , 2006, Cancer research.

[15]  F. Sallusto,et al.  A cyanobacterial LPS antagonist prevents endotoxin shock and blocks sustained TLR4 stimulation required for cytokine expression , 2006, The Journal of experimental medicine.

[16]  S. Akira,et al.  Pathogen Recognition and Innate Immunity , 2006, Cell.

[17]  Hyewon Park,et al.  Receptor activator of NF-κB ligand enhances the activity of macrophages as antigen presenting cells , 2005, Experimental & Molecular Medicine.

[18]  H. S. Warren,et al.  Toll-like receptors. , 2005, Critical care medicine.

[19]  Yibang Chen,et al.  Toll-like receptors on tumor cells facilitate evasion of immune surveillance. , 2005, Cancer research.

[20]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[21]  Shizuo Akira,et al.  Toll-like receptor signalling , 2004, Nature Reviews Immunology.

[22]  S. Kassim,et al.  Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. , 2004, Clinical biochemistry.

[23]  M. Beckmann,et al.  An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. , 2003, Cancer research.

[24]  Z. Duan,et al.  Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. , 2003, Current cancer drug targets.

[25]  Marianne Fillet,et al.  NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells , 2003, Oncogene.

[26]  C. Bucana,et al.  Lipopolysaccharide‐induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion , 2002, International journal of cancer.

[27]  Masao Tanaka,et al.  Lipopolysaccharide increases cyclo-oxygenase-2 expression in a colon carcinoma cell line through nuclear factor-κB activation , 2000, Oncogene.

[28]  U. Matulonis,et al.  Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. , 2000, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[29]  M. Seiden,et al.  TRAG-3, a novel gene, isolated from a taxol-resistant ovarian carcinoma cell line. , 1999, Gene.

[30]  D. Carbone,et al.  Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. , 1998, Blood.

[31]  D. Connolly,et al.  Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome , 1994, The Lancet.

[32]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[33]  Zhi-Yuan Zhang,et al.  Overexpression of insulin-like growth factor binding protein 3 in oral squamous cell carcinoma. , 2008, Oncology reports.

[34]  Shizuo Akira,et al.  Signaling to NF-kappaB by Toll-like receptors. , 2007, Trends in molecular medicine.

[35]  S. Ferrone,et al.  Mechanisms of tumor evasion. , 2005, Cancer treatment and research.

[36]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.